Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients

Summary

This study will test the safety and efficacy of everolimus on heart transplant recipients. This study is not recruiting in the United States.

Timeline

Start

2004-12

Primary completion

2007-05

Completion

—

Publications

• Results Lehmkuhl et al., Transplantation, Volume 88, Number 1, July 15, 2009
• Vigano M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF; RAD A2411 Study Investigators. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis. 2010 Feb;12(1):23-30. doi: 10.1111/j.1399-3062.2009.00448.x. Epub 2009 Sep 9.

Drugs

Indications

No indication recorded.